OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr Moertel on the Importance of Managing MEK Inhibitor–Associated Toxicites in NF1-Associated PN

April 3rd 2025

Christopher L. Moertel, MD, discusses the management of MEK inhibitor–associated toxicities in NF1-associated plexiform neurofibromas.

Dr Vose on the Optimal Role for Epcoritamab in Relapsed/Refractory LBCL

April 2nd 2025

Julie M. Vose, MD, MBA, discusses the optimal use of epcoritamab for select patients with relapsed/refractory large B-cell lymphoma.

Dr Herzberg on Notable Ongoing Research in KRAS-Mutated NSCLC

April 2nd 2025

Benjamin Herzberg, MD, discusses current and future research efforts in KRAS-mutated NSCLC.

Dr Randall on Survey Results for Frozen Margin Sampling in Soft Tissue Sarcoma Resection

April 2nd 2025

Frozen section analysis may be better reserved for high-risk tumor resections, as routine use shows limited benefit and increases cost, survey suggests.

Dr Carles Galceran on the Safety of Darolutamide with ADT and Docetaxel in Older Patients With mHSPC

April 2nd 2025

Joan Carles Galceran, MD, PhD, discusses the safety of adding darolutamide to ADT and docetaxel in older patients with mHSPC.

Dr Merseburger on Real-World Avelumab/Axitinib Discontinuations in Advanced RCC

April 2nd 2025

Axel Merseburger, MD, PhD, discusses AEs associated with real-world treatment discontinuations of avelumab plus axitinib in advanced renal cell carcinoma.

Dr Kopetz on the Safety of Encorafenib Plus Cetuximab in BRAF V600E+ CRC

April 2nd 2025

Scott Kopetz, MD, PhD, FACP, discusses the safety of encorafenib plus cetuximab with/without chemotherapy in BRAF V600E–mutant metastatic colorectal cancer.

Dr Morris on the FDA's Expanded Approval of Lutetium Lu 177 Vipivotide Tetraxetan for PSMA+ mCRPC

April 2nd 2025

Michael J. Morris, MD, discusses the FD expanded approval of lutetium Lu 177 vipivotide tetraxetan for the treatment of patients with PSMA-positive mCRPC.

Dr Chan on the Prevalence of Neuroendocrine Tumors in Young-Adult Patients

April 2nd 2025

Jennifer Chan, MD, MPH, discusses the prevalence of neuroendocrine tumors during Adolescent and Young Adult Cancer Awareness Week.

Dr Dorff on the Safety of Lutetium Lu 177 Vipivotide Tetraxetan in mCRPC With Renal Impairment

April 1st 2025

Tanya B. Dorff, MD, highlights the safety profile of lutetium Lu 177 vipivotide tetraxetan in patients with mCRPC with impaired renal function.

Dr Gupta on Considerations for Frontline Treatment Selection in HR+/HER2-Negative Breast Cancer

April 1st 2025

Tanya Gupta, MD, shares factors informing frontline treatment approaches for metastatic hormone receptor–positive, HER2-negative breast cancer.

Dr Kaiser on Advances With Minimally Invasive Surgery in CRC

April 1st 2025

Andreas M. Kaiser, MD, discusses the benefits of minimally invasive surgery for patients with colorectal cancer.

Dr Lee on Responses With Nivolumab in Resectable dMMR Endometrial Cancer

March 31st 2025

Yong Jae Lee, MD, PhD, discusses key efficacy outcomes with nivolumab monotherapy in completely surgically resectable dMMR endometrial cancer.

Dr Olawaiye on the Potential Role of Afuresertib Plus Paclitaxel in pAKT-Expressing Platinum-Resistant Ovarian Cancer

March 31st 2025

Alexander B. Olawaiye, MD, discusses future research that could inform the use of afuresertib plus paclitaxel in platinum-resistant ovarian cancer.

Dr Hardesty on Updated Data With Frontline Niraparib Plus Bevacizumab Maintenance in Advanced Ovarian Cancer

March 31st 2025

Melissa M. Hardesty, MD, discusses OS and subgroup data from the OVARIO study of niraparib and bevacizumab maintenance in newly diagnosed ovarian cancer.

Dr Duska on the Efficacy of Pembrolizumab Plus Concurrent CRT in Advanced Cervical Cancer

March 31st 2025

Linda R. Duska, MD, MPH, discusses OS and PFS2 outcomes with concurrent pembrolizumab and chemoradiotherapy in high-risk advanced cervical cancer.

Dr Oluwole on AE Mitigation Following Axi-Cel in R/R LBCL

March 31st 2025

Olalekan O. Oluwole, MD, MPH, details the importance of early intervention regarding adverse effects following CAR T products in relapsed/refractory LBCL.

Dr Bowman on the Safety of TKI and Immunotherapy Combinations in Non–Clear Cell RCC

March 31st 2025

Dr Bowman discusses immune-related and TKI-specific toxicities when combining immunotherapy and TKIs in non–clear cell RCC.

Dr Alderuccio on Loncastuximab Tesirine Plus Rituximab in High-Risk R/R Follicular Lymphoma

March 31st 2025

Juan P. Alderuccio, MD, discusses data from loxcastuximab tesirine plus rituximab in high-risk, relapsed/refractory follicular lymphoma.

Dr Myers on HRQOL Outcomes With Mirvetuximab Soravtansine in Ovarian Cancer

March 28th 2025

Tashanna K. Myers, MD, discusses HRQOL findings in patients with platinum-resistant ovarian cancer who received mirvetuximab soravtansine in MIRASOL.